Peptide vendors' crypto payments: $4 million in 2024, $100 million now

In 2024, cryptocurrency payments to online peptide vendors added up to about $4 million, according to blockchain analytics firm Chainalysis. Its projection for 2026, cited in a September 16 report from Johns Hopkins, is more than $100 million. That is a twenty-five-fold jump in two years, in a market that no regulator inspects and almost no laboratory samples.

The blockchain is transparent. The vials are not.

Where the money is going

The Johns Hopkins piece, written by Emily Gaines Buchler and published through Medical Xpress, describes two markets growing at once. One is legal and licensed: compounding pharmacies, an industry the article values at $6.8 billion and expects to nearly double within a decade, are moving into peptides, and telehealth company Hims & Hers has been buying compounding facilities to expand what it can offer. The other is the gray market of anonymous storefronts, forum "stacks" and crypto checkouts, where the "Wolverine stack" of BPC-157 and TB-500 and the multi-compound "Kitchen Sink" are sold by name.

Both markets got a tailwind from the top. In February 2026, Health and Human Services Secretary Robert F. Kennedy Jr. told the Joe Rogan Experience "I'm a big fan" of peptides and predicted the FDA would expand access. In July, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six unapproved peptides for compounded use, a nonbinding recommendation that the agency's own scientists on the panel argued against. Supporters' case was that compounding in U.S. pharmacies is safer than importing gray-market vials. That argument only works if the gray market is as bad as they say. The evidence suggests it is.

Who is making it

Blockchain analytics firm TRM Labs reported in early September that China-based chemical companies which had been producing fentanyl precursors have moved into the peptide business, while continuing to sell precursors to drug cartels, according to Axios reporting summarized by the Partnership for Safe Medicines. Chainalysis had published related findings earlier. The point is not that every gray-market vial comes from such a factory. The point is that nobody buying one can rule it out, because the supply chain behind an anonymous storefront is, by design, invisible.

Eli Lilly, whose investigational triple agonist retatrutide is one of the most copied molecules on those storefronts, has stated flatly that compounded retatrutide is illegal. The FDA's August warning letters to five sellers name it repeatedly.

What the physicians are worried about

Anita Gupta, an anesthesiologist and pharmacist at Johns Hopkins, points to the FDA advisory committee's own review, which documented contaminants and impurities in unregulated peptide products, and notes that the companies selling them don't warn buyers about those findings. Her colleague Christopher Robinson, a physician-scientist, draws the line most people miss: there is a large difference between peptides that went through rigorous trials and were approved as medicines, and newer compounds that have been studied only in mice and rats. The article lists immune reactions ranging from rashes to anaphylaxis among the risks, and notes that perceived benefits may be placebo, since no controlled trial has separated a compound's effect from ordinary healing.

Stanford's Katrin Svensson and Jonathan Long made the same argument a month earlier. Their framing is useful: the human body has roughly 7,000 cataloged peptides acting as cell-to-cell messengers, about 100 peptide therapeutics have been approved by the FDA since insulin in 1921 (first made synthetically in 1982), and the ones on gray-market sites are mostly molecules that were discovered in a lab, tested in mice, and then showed up for sale. In animal studies, they note, some peptides have caused cancer, organ damage, neurotoxicity and amyloid-like plaques. Long-term effects in people are unknown because nobody has looked.

A UCLA review published September 2 adds the material question: products may contain contaminants such as arsenic or lead, are often produced outside the United States, and their actual contents are unknown to the buyer.

What is known, and what isn't

Known: the payment trend, because blockchains are public ledgers and firms like Chainalysis and TRM Labs read them for a living; the enforcement trend, in the FDA's published letters; and the committee's findings on impurities, which are on the public record of the July meeting.

Unknown: what fraction of gray-market vials are contaminated or mislabeled, because no one is sampling them at scale; how much of the $100 million is U.S. buyers versus the rest of the world; and whether the July recommendation, if the FDA adopts it, shifts demand from anonymous vendors to licensed compounders or simply grows both.

What this means for researchers

Provenance is now the whole question. When the same chemical supplier can serve a cartel and a "research" storefront in the same month, a vial's label tells you nothing about what is in it. The only thing that does is a lot-specific analysis from an independent laboratory, and only if it is actually read: which lot, which lab, which tests, what the result was, and whether the report matches the vial in hand.

That is a higher bar than most of the market clears, and it is about to matter more. As the money grows, so does the incentive to cut corners, and so does the attention from regulators, journals and institutional review boards, who can be expected to ask where a study's material came from and how anyone knows. A researcher who can answer that with a document is in a different position from one who can answer it with a screenshot of a checkout page.

The market's growth is real. So is the gap between what is sold and what is known.